Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of autologous cytomegalovirus
(CMV)-specific cytotoxic T cells when given together with temozolomide and to see how well
they work in treating patients with glioblastoma. Autologous CMV-specific cytotoxic T cells
may stimulate the immune system to attack specific tumor cells and stop them from growing or
kill them. Drugs used in chemotherapy, such as temozolomide, may work in different ways to
stop the growth of tumor cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading. Giving autologous CMV-specific cytotoxic T cells with
temozolomide may be a better treatment for patients with glioblastoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Gateway for Cancer Research Marnie Rose Foundation National Cancer Institute (NCI)